Last reviewed · How we verify
Tapered doses of TNFi
Tapered doses of TNF inhibitors gradually reduce the dose of anti-TNF therapy to assess disease control and minimize long-term immunosuppression.
Tapered doses of TNF inhibitors gradually reduce the dose of anti-TNF therapy to assess disease control and minimize long-term immunosuppression. Used for Rheumatoid arthritis in remission or low disease activity, Inflammatory bowel disease in remission, Ankylosing spondylitis in remission.
At a glance
| Generic name | Tapered doses of TNFi |
|---|---|
| Also known as | etanercept 50 mg every 10 days (75% of baseline dose), 14 days (50%), 30 days (25%), adalimumab 40 mg every 3 weeks (75%), 4 weeks (50%), 16 weeks (25%), certolizumab pegol 200 mg 3 weeks (75%), 4 weeks (50%), 16 weeks (25%), golimumab 50 mg every 6 weeks (75%), 8 weeks (50%), 16 weeks (25%), infliximab 5 mg/kg every 8 weeks (75%), 12 weeks (50%), 16 weeks (25%) |
| Sponsor | University Health Network, Toronto |
| Drug class | TNF inhibitor (tapered dosing strategy) |
| Target | TNF-alpha |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
TNF inhibitors (TNFi) block tumor necrosis factor-alpha, a key inflammatory cytokine. Tapering involves systematically reducing the dose while monitoring for disease flare to identify the minimum effective dose, potentially reducing infection risk and other adverse effects associated with prolonged TNF blockade.
Approved indications
- Rheumatoid arthritis in remission or low disease activity
- Inflammatory bowel disease in remission
- Ankylosing spondylitis in remission
Common side effects
- Disease flare upon dose reduction
- Infection (upper respiratory, tuberculosis reactivation)
- Injection site reactions
- Infusion reactions
Key clinical trials
- Spondyloarthritis: Inducing Drug-free Remission by Early TNF-alpha Blockade (PHASE3)
- Biologic Tapering Study of TNF Inhibitors in Axial Spondyloarthritis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tapered doses of TNFi CI brief — competitive landscape report
- Tapered doses of TNFi updates RSS · CI watch RSS
- University Health Network, Toronto portfolio CI